# Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

> **NCT00573989** · PHASE1,PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 27 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** pemetrexed disodium
- **PROCEDURE:** quality-of-life assessment
- **RADIATION:** intensity-modulated radiation therapy

## Key facts

- **NCT ID:** NCT00573989
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Drug Supply Issue
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00573989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00573989, "Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00573989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*